medigraphic.com

2012, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2012; 50 (3)

Preoperative hemostasis evaluation

Vargas-Ruiz ÁG

Language: Spanish
References: 27
Page: 261-266
PDF size: 157.51 Kb.


ABSTRACT

Identify which patients are going to bleed during a surgery or invasive procedure is desirable. The coagulation tests as the prothrombin time (PT), the activated partial thromboplastin time (aPTT), bleeding time (BT) and platelet count are routinely made with this purpose in the preoperative evaluation. But, really these laboratory tests can predict what patients are going to bleed? The answer with the current knowledge is: No. The most efficient method for prediction of bleeding is the clinical history, but still, most surgical bleeding are not by coagulopathy, they are caused by factors related to surgical technique, and therefore are not susceptible to be predicted. This article describes the recommendations for the assessment of bleeding risk prior to surgery or invasive procedures and discusses the value of preoperative coagulation tests.


REFERENCES

  1. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318(18):1162-1173.

  2. Rapaport SI. Preoperative hemostatic evaluation: which tests, if any? Blood 1983;61(2):229-231. Disponible en: http://bloodjournal.hematologylibrary.org/content/61/2/229.long

  3. Laine C, Williams SV, Wilson JF. In the clinic. preoperative evaluation. Ann Intern Med 2009;151(1):ITC1-15, quiz ITC16.

  4. Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol 2008;140(5):496-504.

  5. MacMullen NJ, Dulski LA, Meagher B. Red alert: perinatal hemorrhage. MCN Am J Matern Child Nurs 2005;30(1):46-51.

  6. Nichols WL, Rick ME, Ortel TL, Montgomery RR, Sadler JE, Yawn BP, et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009;84(6):366-370.

  7. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol 2010;148(2):183-194.

  8. Dilley A, Drews C, Miller C, Lally C, Austin H, Ramaswamy D, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001;97(4):630-636.

  9. Kouides PA. Bleeding symptom assessment and hemostasis evaluation of menorrhagia. Curr Opin Hematol 2008; 15(5):465-472.

  10. Rodeghiero F, Kadir RA, Tosetto A, James PD. Relevance of quantitative assessment of bleeding in haemorrhagic disorders. Haemophilia 2008;14(Supl 3):68-75.

  11. Philipp CS, Faiz A, Dowling N, Dilley A, Michaels LA, Ayers C, et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol 2005;105(1):61-66.

  12. Wahlberg TB. A method for the evaluation of clinical information, exemplified for bleeding symptoms in non-severe von Willebrand’s disease type I. Methods Inf Med 1984; 23(3):143-146.

  13. Beran M, Stigendal L, Petruson B. Haemostatic disorders in habitual nose-bleeders. J Laryngol Otol 1987;101 (10):1020-1028.

  14. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003;101(6):2089-2093. Disponible en http://bloodjournal.hematologylibrary.org/content/101/6/2089.long

  15. Dolan G, Hermans C, Klamroth R, Madhok R, Schutgens RE, Spengler U. Challenges and controversies in haemophilia care in adulthood. Haemophilia 2009;15(Supl 1):20-27.

  16. Mannucci PM, Tuddenham EG. The hemophilias–from royal genes to gene therapy. N Engl J Med 2001;344(23): 1773-1779.

  17. Uthman I, Godeau B, Taher A, Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 2008;22(4):187-194.

  18. Watson HG, Greaves M. Can we predict bleeding? Semin Thromb Hemost 2008;34(1):97-103.

  19. Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007;82(7):864-873.

  20. Payne BA, Pierre RV. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984;59(2):123-125.

  21. De Paepe A, Malfait F. Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. Br J Haematol 2004;127(5):491-500.

  22. Eisenberg JM, Clarke JR, Sussman SA. Prothrombin and partial thromboplastin times as preoperative screening tests. Arch Surg 1982;117(1):48-51.

  23. Macpherson CR, Jacobs P, Dent DM. Abnormal perioperative haemorrhage in asymptomatic patients is not predicted by laboratory testing. S Afr Med J 1993;83(2): 106-108.

  24. Houry S, Georgeac C, Hay JM, Fingerhut A, Boudet MJ. A prospective multicenter evaluation of preoperative hemostatic screening tests. The French Associations for Surgical Research. Am J Surg 1995;170(1):19-23.

  25. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77(12):2547-2552. Disponible en http://bloodjournal.hematologylibrary.org/content/77/12/2547.long.

  26. Suchman AL, Mushlin AI. How well does the activated partial thromboplastin time predict postoperative hemorrhage? JAMA 1986;256(6):750-753.

  27. Burk CD, Miller L, Handler SD, Cohen AR. Preoperative history and coagulation screening in children undergoing tonsillectomy. Pediatrics 1992;89(4 Pt 2):691-695.




2020     |     www.medigraphic.com